Kidney-protecting treatment for high-risk upper urinary tract cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to do most daily activities (ECOG 0 to 2).
- Your tumor tests positive for the biomarker HER2 (any level from 0 to 3+).
- You have been diagnosed with high-risk upper urinary tract urothelial cancer on scans and have had a biopsy or brushing sample from the urinary tract.
- Your cancer is considered high-risk (for example, swelling of the kidney from blockage, tumor size ≥2 cm, high-grade tumor, multiple tumors seen in urine tests, or certain past bladder cancer history), and it has not spread to distant organs (M0).
- You need kidney protection now because your kidney function is reduced (eGFR under 60) and you want to protect your kidney.
- You can take study treatment safely: basic blood/clotting tests are acceptable, you’re not pregnant/breastfeeding, and you can avoid certain medicines like steroids and live vaccines around treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an oral targeted drug (DV) and an immunotherapy (Toripalimab) to preserve kidney function in people with high-risk upper tract urothelial cancer (UTUC) who cannot have their kidney and ureter removed. It is for patients with only one kidney, reduced kidney function, or cancer in both ureters.
This trial tests whether injecting a targeted drug (RC48) directly into the bladder after surgery for upper urinary tract cancer can help prevent recurrence in patients whose tumors have high levels of a protein called HER2. The drug is designed to attack cancer cells while minimizing harm to healthy cells.
This trial tests two drugs (disitamab vedotin and tislelizumab) designed to treat a type of cancer in the upper urinary tract (kidney and ureter) while preserving kidney function. It's for patients with HER2-positive tumors who want to avoid or cannot have kidney removal surgery.
This trial tests a combination of targeted therapy (Disitamab Vedotin), immunotherapy (PD-1 inhibitor), and radiation to help avoid bladder removal. It is for people with HER2-high muscle-invasive bladder cancer who have had a maximal transurethral resection (TURBT).
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) and a chemotherapy drug (nab-paclitaxel) to treat kidney pelvis cancer while trying to save as much kidney function as possible. It may be an option if you have a small tumor in the kidney pelvis and are scheduled for a laser procedure.
Hear when a new Upper Urinary Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.